Cardiac Science Aims To Recoup Japan Losses With Biphasic AEDs
This article was originally published in The Gray Sheet
Cardiac Science expects to regain share of the Japanese automatic external defibrillator market with the launch of its biphasic AEDs in Japan, according to CEO Raymond Cohen
You may also be interested in...
AGA Medical will support its second regulatory application in Japan with U.S. data - despite the Japanese health ministry's preference for domestic data - because Japanese trials are prohibitively expensive, according to CEO Franck Gougeon
Cardiac Science anticipates receiving approval from the Japanese Ministry of Health, Labour & Welfare for a biphasic automated external defibrillator by the end of Q2, the firm says
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.